: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.
: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC) trxc stock buy or sell
: The symbol transitioned from TRXC to ASXC as part of this corporate shift. : Shareholders at the time of the merger
: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery". : In March 2021, the company changed its
Since the company is now , it is not possible to buy or sell shares on public markets.
: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.